Related Experiment Video
Updated: Mar 9, 2026
Measuring Post-Stroke Cerebral Edema, Infarct Zone and Blood-Brain Barrier Breakdown in a Single Set of Rodent Brain Samples
Published on: October 23, 2020
Borneol-Edaravone mitigates ischemic brain injury in MCAO rats
Xue-Feng Zhuang1, Tao Zhang1, Yue-Qin Zeng2
1College of Basic Medicine and First affiliated hospital, Kunming Medical University, Kunming, China.
Background:
Borneol-Edaravone, a derivative combining borneol and Edaravone, was evaluated for its neuroprotective and anti-inflammatory effects in a rat model of middle cerebral artery occlusion (MCAO), and its efficacy was compared with Edaravone alone.
Methods:
Borneol-Edaravone was administered intraperitoneally (IP) twice daily, starting at 6 h post-stroke induction and continuing for 7 days. Post-stroke outcomes, including sensorimotor function, neuroprotection, and inflammation markers were assessed.
Results:
As an anti-inflammatory agent(inhibited astrocyte and microglial overactivation, and reduced oxidative/nitrative stress markers (3-NT, 4-HNE), and its effectiveness in improving sensorimotor deficits and reduced cerebral infarct volume in the MCAO, Borneol-Edaravone demonstrated superior neuroprotection to Edaravone.
Conclusion:
These findings suggest that Borneol-Edaravone exerts both neuroprotective and anti-inflammatory effects and may offer enhanced protection with an extended therapeutic window from 4.5 to 6 h against cerebral ischemia-reperfusion injury compared to Edaravone.
